Navigation Links
Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
Date:2/6/2008

MINNEAPOLIS, Feb. 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that it will be presenting at the ROTH Capital Partners OC Growth Conference on Wednesday, February 20, 2008 at the Ritz Carlton Laguna Nigel. David Kaysen, Uroplasty's President and CEO and Medi Jiwani, Uroplasty's Vice President and CFO, will present the Company's business strategy and financial results at 4:00 p.m. Pacific Time.

Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at Uroplasty's website at http://www.uroplasty.com. An archived replay of the presentation will also be available shortly after the live presentation at Uroplasty's website.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Uroplasty Expands Marketing Program for Urology Practices
2. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty to Host Second Quarter Conference Call on November 1
5. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
6. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
7. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
8. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
9. Vical to Present at BIO CEO and Investor Conference
10. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
11. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces ... explains how he was inspired to practice medicine at an early age by his ... more than making diagnoses and prescribing medicine,” he states. “It is about building relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, ... its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing ... shipping and disposal. The new version is a faster and a more efficient ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 The U.S. Food and ... (empagliflozin) to reduce the risk of cardiovascular death in ... disease. "Cardiovascular disease is a leading ... mellitus," said Jean-Marc Guettier , M.D., C.M., director ... FDA,s Center for Drug Evaluation and Research. "Availability of ...
(Date:12/2/2016)... , December 2, 2016 Persistence ... pacemaker market in its upcoming report titled, "Global Market Study on ... Declining CAGR of -1.4% between 2016 and 2024". The global ... in 2015 and this is likely to decline to ... the global cardiac pacemaker market is anticipated to exhibit ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: